SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
CVTX - CV Therapeutics, Inc.
An SI Board Since January 1999
Posts SubjectMarks Bans
411 31 0
Emcee:  Todd N. Weisrock Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
211FDA Grants Priority Review for ACEON(R) Supplemental New Drug Application PR mopgcw-1/10/2005
210Interesting that they didn't come out with these reports last week when the kenhott-12/17/2004
209piper CVTX :Aceon Data Provide Significant Upside Potential 2004-12-16 04:25 (Nemopgcw-12/17/2004
2081st alb: CVTX :Raising Price Target to $35 on Early Stop of ASCOT Clinica Decemmopgcw-12/17/2004
207Interesting PR. CVTX does not get to market the combo product, just Aceon, me tkenhott-12/15/2004
206ASCOT Study Which Included Perindopril Stopped Early Due to Significant Benefit mopgcw-12/15/2004
2051st albany: CVTX :Solvay Deal a Way to Establish a Sales Force 2004-12-08 10:3mopgcw-12/14/2004
204CV Therapeutics and Solvay Pharmaceuticals Enter Into 2004-12-06 16:02 (New Yorkmopgcw-12/7/2004
203Schaeffer's Option Bytes Features CV Therapeutics, Pacific Sunwear of Califomopgcw-11/30/2004
202Has anyone heard what was said at the CIBC Healthcare conference?dbseraf-11/10/2004
201CV place 1.1 million shares w/ acqua well @ $17/share <snip> We are offemopgcw-11/9/2004
2001st Alb: CVTX :Raising Rating on Improved Outlook and Valuation October 28, 20mopgcw-11/2/2004
199CV Therapeutics Reports 2004 Third Quarter Financial Results Tuesday October 26,mopgcw-10/26/2004
198CV Therapeutics Initiates MERLIN TIMI-36 Study of Ranexa(TM) PR Newswire, Mmopgcw-10/12/2004
197Circulation Publishes Study of Ranolazine Demonstrating Important Cardiac Ion Chmopgcw-8/24/2004
196Piper: CV Therapeutics, Inc. Outperform Volatility: Medium Primopgcw-8/2/2004
195FAC: CV Therapeutics, Inc. (CVTX - $ 13.86) In-Line Quarter and a Route tomopgcw-8/2/2004
194CV Therapeutics and FDA Agree to Special Protocol Assessment for Outcomes Study mopgcw-7/29/2004
193Ticker Short Int/Float % Short Int(mln shrs) Float ==========================mopgcw-7/26/2004
192CV Therapeutics and FDA Agree to Special Protocol Assessment for Approval-Enablimopgcw-6/2/2004
191CV Therapeutics Announces Proposed Private Offering of Senior Subordinated Convemopgcw-5/12/2004
190CV Therapeutics Reports 2004 First Quarter Financial Results Friday April 30, 5:mopgcw-4/30/2004
189CV Therapeutics Initiates Second Phase III Trial of Regadenoson Monday April 26,mopgcw-4/26/2004
188JACC Publishes MARISA Trial Results, Including Anti-Ischemic and Long-Term Survimopgcw-4/21/2004
187CV Therapeutics Files Application for European Marketing Approval of Ranolazine mopgcw-3/30/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News